BR112022025245A2 - Terapia de câncer - Google Patents

Terapia de câncer

Info

Publication number
BR112022025245A2
BR112022025245A2 BR112022025245A BR112022025245A BR112022025245A2 BR 112022025245 A2 BR112022025245 A2 BR 112022025245A2 BR 112022025245 A BR112022025245 A BR 112022025245A BR 112022025245 A BR112022025245 A BR 112022025245A BR 112022025245 A2 BR112022025245 A2 BR 112022025245A2
Authority
BR
Brazil
Prior art keywords
therapy
cancer therapy
relates
gram
present
Prior art date
Application number
BR112022025245A
Other languages
English (en)
Inventor
Deban Livija
Levitsky Hyam
Original Assignee
Prokarium Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prokarium Ltd filed Critical Prokarium Ltd
Publication of BR112022025245A2 publication Critical patent/BR112022025245A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

TERAPIA DE CÂNCER. A presente invenção refere-se ao campo de terapia de câncer. Em particular, a presente invenção refere-se a uma bactéria Gram-negativa viva atenuada para uso no tratamento, redução, inibição ou controle de uma doença neoplásica em um indivíduo submetido ou destinado a ser submetido a imunoterapia com uma terapia por inibidor de ponto de controle, uma terapia com célula T adotiva e/ou uma terapia CAR-T alogênica ou autóloga simultaneamente, separadamente ou sequencialmente com a administração da bactéria Gram-negativa viva atenuada.
BR112022025245A 2020-06-10 2021-06-10 Terapia de câncer BR112022025245A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063037179P 2020-06-10 2020-06-10
EP20184698.7A EP3922255A1 (en) 2020-06-10 2020-07-08 Cancer therapy
PCT/EP2021/065698 WO2021250200A1 (en) 2020-06-10 2021-06-10 Cancer therapy

Publications (1)

Publication Number Publication Date
BR112022025245A2 true BR112022025245A2 (pt) 2023-03-14

Family

ID=71607698

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025245A BR112022025245A2 (pt) 2020-06-10 2021-06-10 Terapia de câncer

Country Status (11)

Country Link
US (3) US11529378B2 (pt)
EP (2) EP3922255A1 (pt)
JP (1) JP2023529957A (pt)
KR (1) KR20230023731A (pt)
CN (1) CN116113426A (pt)
AU (1) AU2021288622A1 (pt)
BR (1) BR112022025245A2 (pt)
CA (1) CA3186261A1 (pt)
IL (1) IL298865A (pt)
MX (1) MX2022015623A (pt)
WO (1) WO2021250200A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3922255A1 (en) * 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
GB9910812D0 (en) 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
GB0327056D0 (en) 2003-11-20 2003-12-24 Cobra Biolog Ltd Plasmid maintenance
US8221739B2 (en) * 2004-04-29 2012-07-17 Botanic Oil Innovations, Inc. Method of cancer treatment
GB201011046D0 (en) 2010-06-30 2010-08-18 Rph Pharmaceuticals Ab Plasmid maintenance
EP2801364A1 (en) * 2013-05-07 2014-11-12 Centre Hospitalier Universitaire Vaudois (CHUV) Salmonella strain for use in the treatment and/or prevention of cancer
US20180064765A1 (en) * 2014-07-18 2018-03-08 Advaxis, Inc. Listeria-based immunogenic compositions for eliciting anti-tumor responses
US20230158133A1 (en) * 2016-11-04 2023-05-25 Vaximm Ag Wt1 targeting dna vaccine for combination therapy
WO2018106754A1 (en) * 2016-12-07 2018-06-14 Md Biosciences, Inc. Methods of synergistic treatment of cancer
EP3495469A1 (en) 2017-12-07 2019-06-12 Prokarium Limited Vaccine compositions ii
EP3844276A2 (en) * 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
AU2019376140A1 (en) 2018-11-08 2021-06-03 Synlogic Operating Company, Inc. Combination therapies of microorganisms and immune modulators for use in treating cancer
US10806778B2 (en) 2019-01-30 2020-10-20 Prokarium Limited Modified strain of Salmonella enterica Typhi
US20220125906A1 (en) * 2019-02-27 2022-04-28 The General Hospital Corporation Treatment of benign nervous system tumors using attenuated salmonella typhimurium
WO2021071468A1 (en) 2019-10-07 2021-04-15 Nantcell, Inc. Neoepitope vaccine and immune stimulant combinations and methods
EP3922255A1 (en) * 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy

Also Published As

Publication number Publication date
JP2023529957A (ja) 2023-07-12
IL298865A (en) 2023-02-01
WO2021250200A1 (en) 2021-12-16
AU2021288622A1 (en) 2023-02-02
KR20230023731A (ko) 2023-02-17
US20230143897A1 (en) 2023-05-11
EP4164662A1 (en) 2023-04-19
CN116113426A (zh) 2023-05-12
US20210386794A1 (en) 2021-12-16
US11529378B2 (en) 2022-12-20
EP3922255A1 (en) 2021-12-15
US20220354904A1 (en) 2022-11-10
CA3186261A1 (en) 2021-12-16
MX2022015623A (es) 2023-03-15

Similar Documents

Publication Publication Date Title
Bitschar et al. Lugdunin amplifies innate immune responses in the skin in synergy with host-and microbiota-derived factors
CY1124488T1 (el) Απελευθερωση πρωτεϊνης που βασιζεται σε εξασθενημενης λοιμογονικοτητας βακτηριδια
Kurlenda et al. Alternative therapies in Staphylococcus aureus diseases
CY1122191T1 (el) Βακτηριο για χρηση ως προβιοτικο για διατροφικες και ιατρικες εφαρμογες
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
BR112022002442A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
MX339451B (es) Composiciones y metodos para inmunoterapia.
PH12019500360A1 (en) Antibiotic compounds
BR112023022819A2 (pt) Compostos, composição farmacêutica, conjugados e métodos para tratar câncer em um sujeito, para tratar um distúrbio e para inibir uma proteína ras em uma célula
BR112022025245A2 (pt) Terapia de câncer
BR112021020247A2 (pt) Composições e métodos para melhorar a saúde da pele e para o tratamento e prevenção de doenças, distúrbios e afecções associadas a micróbios patogênicos
MX2023004032A (es) Terapias inmuno-oncologicas con conjugados de il-2.
BR112022007158A2 (pt) Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
BR112018009753A8 (pt) bactérias de virulência atenuada para o tratamento de tumores sólidos malignos
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
Muhammad et al. Novel epidermal growth factor receptor pathway mediates release of human β-defensin 3 from Helicobacter pylori-infected gastric epithelial cells
Lee et al. Heat-killed Mycobacterium paragordonae therapy exerts an anti-cancer immune response via enhanced immune cell mediated oncolytic activity in xenograft mice model
BR112016023011A2 (pt) tratamento de câncer gástrico
MX2020011738A (es) Uso de calcifediol en pacientes de cirugia bariatrica.
Bornstein et al. Photodamage to Multidrug‐resistant Gram‐positive and Gram‐negative Bacteria by 870 nm/930 nm Light Potentiates Erythromycin, Tetracycline and Ciprofloxacin
BR112023026660A2 (pt) Armadilhas do ligante fator de crescimento transformante-beta para o tratamento de doença
BRPI0806257A2 (pt) método de tratamento, e, uso de uma composição imunoterapêutica
BR112023019407A2 (pt) Composições farmacêuticas compreendendo zolmitriptano
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
EA202290048A1 (ru) Лекарственное средство и его применение для лечения бактериальных инфекций, связанных с биопленкой